滤泡淋巴瘤新靶向药物治疗机制与临床选择  

Mechanisms of new targeted drugs in follicular lymphoma and clinical options

作　　者：冯晓蒙 白鸥[1] Feng Xiaomeng;Bai Ou(Department of Hematology,the First Hospital of Jilin University,Changchun 130000,China)

机构地区：[1]吉林大学第一医院血液科,长春130000

出　　处：《白血病．淋巴瘤》2021年第7期441-444,共4页Journal of Leukemia & Lymphoma

摘　　要：滤泡淋巴瘤是最常见的惰性淋巴瘤,目前常用免疫化疗方案治疗,但进展及复发患者预后较差。新靶向药物包括细胞表面抗体、免疫调节剂、细胞信号通路激酶抑制剂、嵌合抗原受体T细胞疗法、树突细胞疫苗等显著延长患者的生存期,为临床治疗提供新的选择。Follicular lymphoma is the most common indolent lymphoma.At present,it is commonly treated with immunochemotherapy,but the prognosis of patients with progression and relapse is still poor.New targeted drugs include cell surface antibodies,immunomodulators,cell signaling pathway kinase inhibitors,and chimeric antigen receptor T cell therapy and dendritic cell vaccines have greatly extended the survival period of these patients and provided more options for clinical treatment.

关 键 词：淋巴瘤 滤泡型 药物疗法 联合 组织疗法 免疫调节 

分 类 号：R733.1[医药卫生—肿瘤]